Quantcast

Latest AbbVie Stories

2014-05-16 23:09:18

The Long Island, New York law firm of Rudolph F. X. Migliore, P. C. has announced the Judicial Panel on MultiDistrict Litigation has scheduled a hearing session to consider consolidating lawsuits against AbbVie. Commack, New York (PRWEB) May 16, 2014 AbbVie, the makers of Androgel, allegedly made a defective medical product and hiding information about the defective drug Androgel, according to a number of federal lawsuits. The Judicial Panel on MultiDistrict Litigation has scheduled a...

2014-05-15 12:35:08

New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas NORTH CHICAGO, Ill., May 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline. Dr. Severino's...

2014-05-13 08:31:40

NORTH CHICAGO, Ill., May 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition...

2014-05-08 04:21:41

- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date1 NORTH CHICAGO, Ill., May 8, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The MAAs are supported by...

2014-04-23 08:31:41

- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative...

2014-04-22 08:34:00

-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by...

2014-04-16 12:30:01

- Scholarship recognizes 40 exceptional students with cystic fibrosis (CF) who serve as role models for the community through academic excellence, creativity and community service NORTH CHICAGO, Ill., April 16, 2014 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship, which honors young adults with CF as they pursue higher education. Students can apply for the scholarship...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...

2014-04-12 00:21:23

- In patients with compensated liver cirrhosis and genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, a difficult-to-treat population, TURQUOISE-II demonstrated SVR(12) rates of 91.8 and 95.9 percent after 12 and 24 weeks of treatment, respectively LONDON, April 12, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver Congress(TM) (ILC) 2014. Data from a pivotal phase...

2014-04-11 00:21:52

-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic hepatitis C virus infection LONDON, April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference....


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'